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Summary 
 
Plp-tg (proteolipid protein gene transgenic) mice are hemizygous mice (Plptg/-). These 
mice were first generated by Tetsushi Kagawa and colleagues (Kagawa et al., 1994). 
They have two additional copies of the Plp gene and express about 30 % more Plp 
transcripts than wild-type (WT) mice. In previous research, these mice were found to 
have ultrastructurally normal myelin before 3 months-old. After that, Plp-tg mice begin to 
show signs of degeneration of myelin. After 7 months of age, most axons of Plp-tg mice 
are demyelinated and the remyelination of those axons are impaired at this stage (Kagawa 
et al., 1994; Inoue et al., 1996). The mechanisms of long-term demyelination and the 
impairment of remyelination are not known yet. 
 
Many models for studying human multiple sclerosis (MS) have been proposed. Most of 
them aim to model the initial phase of MS. However, few mimic the late, chronic 
demyelinating phase. In contrast to the early phase, the chronic lesions of MS are not 
remyelinated. Because enhancement of remyelination is a promising therapeutic strategy, 
studies of the mechanisms that lead to chronic demyelination are important. Models, such 
as the Plp-tg mouse, that mimic the late stage of MS are indispendable.  
 
The present study investigated the mechanism of demyelination and the impairment of 
remyelination in the Plp-tg mouse. We found that from 2 months old, the ratio of 
immature to mature oligodendrocytes in Plp-tg mice kept rising until it reached a peak at 
5 months old. The long-term demyelination and impairment of remyelination is probably 
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caused by the presence of only a low number of mature oligodendrocytes (OLs), resulting 
in an inability to maintain and form myelin. However, the underlied mechanism is not 
attributable to a deficit in oligodendrocyte progenitors (OPCs) expressing NG2. On the 
contrary, such immature OLs are present in even higher numbers in the demyelinated 
spinal cord of the transgenic mice than in WT controls. The rate of proliferation of OPCs 
was similar in both WT and Plp-tg mice, while there were higher rates of apoptosis of 
mature OLs in Plp-tg mice. Thus, it appears that the higher ratio of immature to mature 
OLs in Plp-tg mice is probably due to the failure of terminal differentiation of 
oligodendrocytes and to the high rate of apoptosis in mature oligodendrocytes. There was 
greater expression of CD4+ T cells, CD8+ T cells and microglia in the spinal cord of Plp-
tg mice suggesting that cytokines secreted by actived CD4+ T cell, microglia and CD8+ 
T cells together with CD8+ T cell cytotoxic effects may cause the apoptosis of mature 
oligodendrocytes in Plp-tg mice. We suggest that cytokines produced by CD4+ T cells, 
and microglia may also inhibit oligodendrocyte terminal differentiation, although further 
experiments need to be carried out to investigate this hypothesis.  
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1.1 CNS Myelination 
During evolution, most vertebrate species have developed two specialized glial cell types 
that form myelin: the Schwann cells in the peripheral (PNS) and the oligodendrocytes 
(OLs) in the central nervous system (CNS). Schwann cells are neural crest derivatives 
(Jessen and Mirsky, 1992), while OLs are derived from more restricted domains of the 
embryonic CNS, such as the ventral aspect of the ventricular zone of the neural tube 
(Miller and Ono, 1998). From these locations, the oligodendrocyte precursor cells (OPCs) 
migrate into the primordial white matter tracts of the CNS, where they pass through 
distinct developmental stages and eventually acquire the typical phenotype of 
myelinating OLs (Miller and Ono, 1998). The proteolipid protein (PLP) and its isoform 
DM20 are major constituents of CNS myelin. Although there’re many researches on the 
spontaneous or engineered mutants, the functional roles of the proteins are not yet clear 
(Griffiths et al, 1998). What can be extracted from studies in mutant animals is that, like 
several other myelin constituents, PLP proteins are dosage sensitive: i.e., either over- or 
under-expression leads to abnormalities in myelination. In addition, PLP might be a 
structural component of CNS myelin and is a candidate to mediate interactions between 
OLs and axons. Dependent on the type of mutation, and possibly on the involvement of 
modifying genes, PLP mutants show a large spectrum of severity ranging from severe 
dysmyelination due to OL death to mild and late demyelinating phenotypes. Mutations in 
the Plp gene also occur in human MS (Tuohy et al, 1997).  
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Figure 1. Schematic diagram illustrating the genesis and maturation of oligodendrocytes 
and characteristic protein markers expressed by the cell types at each stage. Adapted form 
Zhang SC. 2001. Nature reviews. Neuroscience. 2(11):840-3. 
 
1.1.1   Oligodendrocyte differentiation 
The OL lineage can be classified into five stages by its morphology, antigen expression 
and physiology character (Dubois-Dalcq and Armstrong, 1992; Pfeiffer et al., 1993; 
Armstrong et al., 1995). In the first stage, preprogenitor cells proliferate as spheres that 
resemble neural precursor cells (NPCs) (Figure not shown). In the second stage, 
Oligodendrocyte progenitors (OPCs) exhibit bipolar morphology, proliferating and 
migrating ability. In the third stage, pro-oligodendrocytes show decreased proliferation 
and migration capacity, and have a bifurcated morphology. They further progress into the 
fourth stage as immature OLs. These are postmitotic and non-migratory cells. The fifth 
and final stage is mature OLs that elaborately wrap target axons and form myelination.  
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The chondroitin sulphate proteoglycan (NG2), is used as markers for the proliferative and 
migratory OPCs, while  2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) is a 
marker for mature OLs.  
 
1.1.2   Myelination 
CNS myelination depends on OL maturation (Wang et al., 1998). Antigenically, 
myelinating OLs start to express myelin-associated glycoprotein (MAG) (Quarles et al., 
1973), all four isoforms of myelin basic protein (MBP) (Martenson et al., 1969) and PLP 
(Wolfgram, 1966), which constitutes a major component of myelin (Richter-Landsberg 
and Heinrich, 1996). At this stage, OLs spread out and wrap the axon repeatedly and 
tightly, thus forming an insulated structure around the axon, which is the physiological 
basis for rapid action potential conduction (Hille, 2001). 
 
1.2   Multiple Sclerosis (MS) 
Because of the uncertainty of diagnosing MS, no one knows exactly how many people 
have MS. It is believed that there are approximately 250,000 to 350,000 people in the 
United States with MS and approximately 3 million live with it worldwide. Most people 
experience their first symptoms between the ages of 20 and 40 years and will suffer over 
many years. The annual cost of MS in the US has been estimated to be $2.5 billion. 
(National Institute of Neurological Disorders and Stroke. Multiple Sclerosis: Hope 
through Research. NIH. 2002.  
http://www.ninds.nih.gov/health_and_medical/pubs/multiple_sclerosis.htm). 
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MS is widely believed to be an autoimmune disease. It is characterized by multiple 
lesions of the CNS myelin and chronic clinical signs from axonal damage (Keegan and 
Noseworthy, 2002). In MS patients, autoantibodies and autoreactive T cells activated 
against myelin antigens such as MBP, PLP, and myelin oligodendrocyte glycoprotein 
(MOG) have been found (Garren et al., 1998). It is generally believed that MS arises 
from damaged myelin sheaths with impaired nerve conduction which caused by T 
lymphocytes reacting against myelin components, activate microglia and macrophages 
(Hohlfeld and Wekerle, 2001; Steinman et al., 2002). Most MS researchers consider it as 
a CD4+ T-helper 1 (Th1)-mediated inflammatory demyelinating disease (Martin et al., 
1992; Hafler, 2004). The majority of MS patients has an initial relapsing–remitting 
course for 5 to 15 years and then follows a secondary progressive neurologic disability 
(Weinshenker, 1989). Relapses result from inflammation and demyelination, while 
remission is accompanied by resolution of inflammation, redistribution of sodium 
channels on demyelinated axons, and remyelination (Waxman, 1998; Trapp, 1999).  
 
The pathology of MS is indicated by data from several sources, including the cellular 
composition of brain and cerebrospinal fluid (CSF)-infiltrating cells and data from 
studies of the Experimental Allergic Encephalomyelitis (EAE) model, a widely used 
animal model for MS (Muthian, Bright, 2004). In one of the EAE model, myelin 
components in complete Freund's adjuvant (CFA) are injected into susceptible animals. 
This can lead to a CD4+-mediated autoimmune disease which is very similar with MS in 
clinical, immunological and pathological properties(Zamvil, Steinman, 1990; Imrich, 
Harzer, 2001). However, CFA only creates an artificial inflammatory circumstance that 
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does not reflect the natural environment and self- or mimic-peptides would be seldom 
encountered. There are also other ways of producing an EAE model, such as transferring 
anti-myelin activated T-cells to naive animals(Zamvil, Steinman, 1990). This clearly 
indicates the autoimmune component of the MS disease. 
 
1.2.1 Microglia and MS 
Microglia are mainly found in mammalian CNS and have been traditionally regarded as 
CNS macrophages. Since microglia are the vital members of the innate immune system, 
they are important in determining neural-immune interactions under both physiologic and 
pathologic conditions. Microglia are active participants throughout the MS disease 
process. They can act as antigen presenting cells (APCs) in CNS, initiating and 
propagating immune responses, phagocytosing dying cells and debris, and producing 
toxic innate effectors (Williams et al., 1994; Minagar et al., 2002; Nelson et al., 2002).  
 
1.2.1.1 Microglial activation 
Evidences show that mammalian microglia express a wide array of conserved innate 
receptors- toll-like receptor (TLRs), including mRNA for TLRs 1–9(Bsibsi et al., 2002; 
Olson, Miller, 2004). Through the ligation of TLRs, Mammalian microglia can recognize 
danger signals and can be activated and induce an inflammatory response.  
 
Peptidoglycan (PGN) is the classic ligand for TLR2, which has been detected in the CNS 
of MS patients. (Schrijver et al., 2001). Kielian et al. found PGN are able to stimulate 
innate activation of microglia by producing pro-inflammatory cytokine and chemokine 
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(Kielian et al., 2002). They also found that the effect of PGN was critically dependent on 
TLR2. They used TLR2-deficient mice for the test. After stimulating the mice with PGN, 
they demonstrated reduced cytokine and chemokine production comparing with WT. 
(Kielian et al., 2005). Bacterial lipopolysaccharide (LPS) is a known TLR4 ligand.  
Researches found murine microglial could be activated and produce pro-inflammatory 
responses when binding LPS, which resulted in dramatic injury to cultured 
oligodendrocytes and neurons (Lehnardt et al., 2002; Lehnardt et al., 2003).  
 
1.2.1.2 Microglia act as APCs 
The sites in the blood–brain barrier (BBB) and within the CNS parenchyma are the main 
location of antigen presentation in the CNS. At each site, competent antigen presentation 
is dependent on cells expressing both the requisite MHC and costimulatory molecules. 
Since microglia can express MHC class II with costimulatory molecules in the CNS of 
MS patients, they have the potential to activate CD4+ Th1 cells (Aloisi et al., 2000). 
Researchers have found that when isolated human parenchymal microglia and tested in 
vitro, they are shown to have the competent APCs properties (Williams et al., 1993). 
Aloisi et al. also found that microglia isolated from newborn rodents and humans and 
activated by proinflammatory cytokines such as gamma interferon (IFN-γ), microglia are 
capable of functioning as APCs in vitro (Aloisi et al., 2000).What’s more, another 
important kind of APCs--macrophages can also be derived from microglia. Williams et al. 
(1992) and Becher and Antel (1996) found parenchymal microglia can differentiate into 
perivascular macrophages (Williams et al., 1992; Becher, Antel, 1996). When those 
macrophages are isolated and tested in vitro, they could be shown to have competent 
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APCs properties (Ford et al., 1995). Microglia and/or their partners--macrophages can 
present antigen to T cells and activate them. Regulation of microglia-T cells-
macrophages may play an important role in the inflammatory lesions. 
 
1.2.1.3 Tissue injury caused by microglia in MS 
As discussed above, after danger signals binding innate receptors such as the TLRs, 
microglia may be activated and secrete toxic cytokines. Microglia play a vital role in MS 
lesion throughout all phases of MS disease (Lassmann, 2003). In acute MS stage, these 
cells destroys myelin components and produce lymphocyte inflammatory response. 
During chronic MS stage, lesion is mainly caused by activated microglia/macrophages 
not by lymphocyte. (Trapp, 2004). Cytotoxic cytokines produced by microglia can 
directly cause injury and loss of the OLs and myelin. According to pathologic analyses, 
the restricted injury to the myelin membrane or OLs is the main cause of MS 
demyelination (Lucchinetti et al., 2000). In addition to production of pro-inflammatory 
cytokines and up-regulation of cell surface activation antigens, as the vital members of 
the innate immune system, microglia could also have phagocytosis function after 
activation.  
 
1.2.2 CD4+ T cells and MS 
T lymphocytes can be divided into CD4+ and CD8+ expressing T cells. Usually, CD4+ T 
helper cells (TH) recognize peptides that are presented by MHC class II APCs. Once 
activated, naive TH cells differentiate into functional subsets: TH1 and TH2 cells. The 
TH1 cells are called as pro-inflammatory cells which predominantly produce IFN -γ and 
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tumour necrosis factor (TNF) - α and protect against intracellular pathogens. While TH2 
cells produce interleukin (IL)-4, IL-5 and IL-13, and help to combat extracellular 
infections (Seder and Ahmed, 2003).  
 
In general, many more Th1 cells are permitted infiltration than Th2 cells by the brain 
immune surveillance system (Kivisa, et al. 2003). Therapeutic strategies of inducing a 
shift from Th1 to Th2 immune reactions have shown beneficial effects in MS patients 
(Hohlfeld, R. 1997). There are also some indirect evidences suggesting that CD4+-Th1 
cells may play a role in MS (Stefferl, A. et al. 1999; Lucchinetti, C.F. et al. 2002). In 
some MS patients, T-cells with MBP receptor have been found in MS brain lesions 
(Oksenberg, J.R. et al. 1993) and immune peptides anti- MBP are found at sites of 
demyelination (Krogsgaard, M. et al. 2000). The genetic studies show an association of 
MS susceptibility with genes in the MHC class II region (Herrera, B.M. and Ebers, G.C. 
2003). All these data suggest that MS mainly develops in genetically susceptible 
individuals when autoimmune CD4+-Th1 cells are locally activated. 
 
1.2.3 CD8+ T cells and MS 
CD8+ T cells recognize peptides from endogenous antigens presented by MHC class I 
molecules which are expressed by all nucleated cells. They induce an immune response  
not only through production of cytokines, such as IFN -γ and TNF-α, but also by direct 
cytotoxicity (Wong and Pamer, 2003). Unlike CD4+ T cells, CD8+ T cells function in 
inducing MS is often been overlooked. However, many scientists now found that CD8+ T 
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cells also play an important role in MS (Neumann et al., 2002; Lassmann and Ransohoff, 
2004). 
 
 CD8+ T cells can only be activated by MHC class I APCs with co-stimulatory molecules. 
Since it has long been accepted that the CNS is lack of MHC class I molecules, CD8+ T 
cells function in CNS inflammation in MS is often been overlooked. However, in vitro, 
OLs can be induced by gamma interferon (IFN-γ)，a proinflamating cytokine secreted 
by CD4+ etc., to express MHC class I antigen(Grenier et al., 1989). Neumann et al. (2002) 
also found that most neuronal cells and glia can express MHC class I when stimulated in 
vitro with IFN-γ (Neumann et al., 2002).  
 
What’s more, Ransohoff and Estes (1991) and Gobin et al. (2001) all found the 
expression of MHC class I is upregulated in MS (Ransohoff, Estes, 1991; Gobin et al., 
2001). After infiltrating into the CNS, the activated CD8+ T cells can recognize the 
antigen on MHC class I presenting cells and attack them (Ramakrishna et al., 2004). It 
seems that many of the CD8+ T cells in MS are first stimulated in the periphery and then 
migrate into the CNS, become activated and cause cytotoxic damage especially to OLs 
and cause demyelination in CNS (Kivisakk et al., 2004). Cytokines and direct 
cytotoxicity produced by CD8+ T cell could contribute to OLs destruction in MS. 
However, there are also some CD8+ T regulator cells can partly control the autoimmune 
responses in EAE, by modulating the TH phenotype of self-reactive CD4+ T cells(Jiang 
et al., 2001). 
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1.3 Plp-tg mice, an animal model of MS 
1.3.1 Proteolipid protein (PLP) 
PLP is the most abundant myelin protein in the mammalian CNS. It localizes mainly in 
compact myelin. Plp gene comprises 7 exons. Its transcriptional unit is about 17kb long. 
The 5’ region contains both positive and negative regulatory sequences and intron 1 is 
also believed to contain regulatory elements (Wight and Dobretsova, 1997; Wight et al., 
1997). There’s an internal donor splice site in exon 3 which allows the generation of the 
shorter Dm20 message isoform from the primary transcript (Nave et al., 1987). PLP and 
DM20 are identical except DM20 doesn’t have residues 116 to 150. Like other myelin 
genes, the major regulation of the Plp gene is at the transcriptional level although post-
transcriptional and translational regulation also operates. The major site of Plp gene 
expression is the oligodendrocyte. PLP (and/or DM20) probably has more than one 
function besides the formation of myelin. They may also have function in glial to axon 
communication in myelinated nerve fibres (Kitagawa et al., 1993; Knapp, 1996). 
 
1.3.2 Plp-tg mice 
Several Plp gene overexpression transgenic mouse lines have been established (Inoue et 
al., 1996; Kagawa et al., 1994; Readhead et al., 1994). The transgenes are expressed in 
the correct temporospatial manner. It seems that mice from all these lines form a 
phenotype depend on the excess number of copies of the transgene and whether it is in a 
homozygous or hemizygous manner. 
 
We selected the hemizygous transgenic mice from 4e line of Kagawa et al and Inoue et 
al. (Kagawa et al., 1994; Inoue et al., 1996.). The homozygous mice (Plptg/tg) that have 4 
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additional copies of Plp gene showed severely defective oligodendrocyte maturation, 
dysmyelination, tremors and convulsions, and die by 4 weeks of age. The hemizygous 
mice (Plptg/-) which bear 2 more copies of Plp gene showed a decrease in the number of 
mature OLs and show demyelination. The young animals (<3 months of age) have 
ultrastructurally normal-appearing myelin. After that, Plptg/- mice begin to show signs 
of myelin degeneration, and from 3–7 months of age, myelin destruction/degeneration 
in a stage-dependent manner appears. After 7 months of age, most axons of Plptg/- mice 
are demyelinated and their remyelination are impaired at this stage (Kagawa et al., 1994; 
Inoue et al., 1996). 
 
1.3.3 Plp-tg mice act as a model for MS 
In the clinic, MS includes four major stages: relapsing-remitting (RR), secondary 
progressive (SP), primary progressive (PP) and progressive relapsing (PR). 
Remyelination takes place in the early stages of MS but seldom in the late phase. Late 
stages of MS are characterized by chronic demyelination and impairment of 
remyelination. Studies on the mechanisms that lead to impaired remyelination are 
important for seeking strategies for treatment (Franklin, 2002; Lubetzki et al., 2005). 
Though various animal models are available for studying human MS, EAE is the most 
widely used. However, EAE does not represent the late chronic phase of demyelination 
observed in the progressive course of MS well. Hence, an animal model that mimics the 
process of late phase MS is essential (Jianmei ma et al. 2005). 
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The hemizygous (Plptg/-) mice in the ‘4e’ line (Kagawa et al., 1994; Inoue et al., 1996) 
are good models for late stage MS. Two or 3 months after birth, degeneration of the 
myelin sheath occurs, and this degeneration proceeds slowly until 6 months after birth. 
During this period, heterozygote mice showed little or no abnormality in their behavior. 
After 6 months of age, they began to show hindlimb tremors and paralysis and other 
abnormal behavior. This was accompanied by severe demyelination, and at around 7 
months after birth, most of the axons became naked. There is also extensive infiltration of 
microglia-like cells (microglia or macrophages) (Kagawa et al., 1994; Inoue et al., 1996). 
This suggests that the lesions of myelination are most likely to be caused by an 
autoimmune response, as in human MS. Little is known about the mechanisms by which 
remyelination ceases. 
 
1.4   Aims and significance of the present study 
1.4.1. To investigate the ratio of immature to mature OLs 
The first major aim of the present study was to investigate immature and mature OLs to 
explore the pathological changes underlying chronic demyelination and impaired 
remyelination in Plp-tg mice.  
 
Kagawa et al and Inoue et al. (Kagawa et al., 1994; Inoue et al., 1996) reported that the 
demyelination in Plp-tg mice correlated with a decrease in the number of mature OLs. 
They suggested that this was indicative of an arrest in oligodendrocyte maturation. 
However, their findings came from studies by EM and they were unable to determine 
whether the change was the result of a deficit in OPCs, a decrease in the population of 
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mature OLs, or some other mechanism. To elucidate the mechanism of the demyelination 
and failure of remyelination in Plp-tg mice, we investigated the ratio of OPCs to mature 
OLs dynamically over time and compared the rates of OL apoptosis and OPC 
proliferation between wt and Plp-tg mice. 
 
1.4.2. To determine the mechanisms underlying the pathological changes in OLs and 
myelination 
The second major aim of the present study was to investigate the mechanisms underlying 
the pathological changes in the OLs and myelination of the Plp-tg mice. Elucidation of 
these mechanisms may inform further studies seeking new treatment strategies for MS. 
Kagawa et al and Inoue et al. also found that there was extensive infiltration of microglia-
like cells (microglia or macrophages) in the CNS of Plp-tg mice. (Kagawa et al., 1994; 
Inoue et al., 1996). In the present study, we immunostained for microglial subtypes to 
investigate the nature of these cells. We checked for expression of CD11b+, a marker of 
microglia, dynamically over the time course of demyelination in Plp-tg mice. Since 
microglia activation is often induced by CD4+ T cell infiltration and CD4+ T cells and 
CD8+ T cells appear to play important roles in MS, we also investigated CD4+ T cell and 
CD8+ T cell expression levels dynamically in the CNS comparing with Plp-tg mice and 











Materials & Methods 
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2.1 Materials 
2.1.1   Antibodies 
2.1.1.1   Primary antibodies 
Tables 1 and 2, below, indicate the source of the primary antibodies. 
Table 1. Monoclonal antibodies 
FITC-conjugated CD4(L3T4)  BD Biosciences Pharmingen 
FITC-conjugated CD8(Ly-2) BD Biosciences Pharmingen 




 Table 2. Polyclonal antibodies 
Rabbit anti-mouse active caspase-3  Chemicon International  
Rabbit anti-mouse Ng2 Chemicon International 
 
2.1.1.2 Secondary antibodies 
Secondary antibodies used were: Cy3 (red) and Cy2 (green) labelled goat anti-rabbit IgG, 
Cy3 (red) and Cy2 (green) labelled rabbit anti-mouse IgG (Amersham Pharmacia Biotech 
UK Limited), Alexa Fluor® 488(green) labelled goat anti rabbit IgG, Biotinylated rabbit 
anti-mouse IgG (Vector, USA).  
 
2.1.2 Other Materials 
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Other materials used were fluorescence mounting medium with DAPI (Vector), ABC kit 
(Vector, USA), DAB (Vector, USA), BrdU powder (Sigma), PCR kit (QIAGEN). All 
other reagents were purchased from Sigma unless otherwise stated. 
 
2.2 Methods 
2.2.1 Plp-tg mice genotyping 
Plp transgenic mice with extra copies of the Plp gene (Kagawa et al., 1994) were bred to 
C57BL/6 (WT) mice to get heterozygosity. Transgenic mice were genotyped using DNA 
obtained from tail clips, which was amplified by polymerase chain reaction (PCR). 
Special primers were used for DNA amplification. Samples were incubated with 1.5μl 
forward primer(10 μM) (5`-CAATGCGCTTACTGATGCGG-3`) and 1.5μl reverse 
primer (10 μM) (5`-CGCACAGAAGCTATTATGCG-3`) for 35 cycles in a GenAmp 
PCR system at 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 30 seconds. The 
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Figure 2  Genotyping of Plp-tg mice 
         A    B     C    D    E    F   G    H    I      J    K   L    M   N   
 
Lane A: DNA ladder 
Lane B-K: positive Sample (Plptg/-) 
Lane L:   negative control (wt) 
Lane M:  Positive control (Plptg/-) 
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2.2.2 Double immunostaining of spinal cord sections for NG2 and CNPase 
2.2.2.1   Perfusion and dehydration 
Plp-tg mice of 2 months-, 3months-, 5months-, 7months- old and WT mice of 2months-, 
5months- old were deeply anesthetized with 7% chloral hydrate and transcardially 
perfused with Ringer’s solution, followed by 4% paraformaldehyde in 0.1 M sodium 
phosphate buffer (PB) (pH 7.4). The cervical spinal cord was removed and post-fixed in 
the same fixative for another 2 days. Then the tissue was transferred to 15% sucrose 
solution at 4°C overnight and then to 30% sucrose solution overnight. 
 
2.2.2.2   Cryosectioning 
The tissue was immersed in the embedding medium (Sakura) and frozen in liquid 
nitrogen. The tissue block was mounted and 10 μm cross sections were cut on a Leica™ 
Cryostat. The sections were harvested onto 1.5% gelatin-treated glass slides and allowed 
to dry at room temperature (RT) for 2 hours. 
 
2.2.2.3   Permeabilization and blocking 
The sections were permeabilized by washing with phosphate-buffered saline (PBS)/3% 
Triton-X 100 for 3 times (each time 10 minutes) and with 4°C acetone for 15 minutes. 
Then the sections were washed with PBS and blocked with 10% goat serum in PBS/3% 
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2.2.2.4   Antibody incubation 
The Sections were incubated in Rabbit anti mouse NG2 (1:200 in PBS) polyclonal 
antibody in RT overnight. Then they were washed with PBS/3% Triton-X 100 for 3 times 
(each time 5 minutes). The sections were incubated in secondary antibody Alexa Fluor® 
488(green) labelled goat anti rabbit IgG (1:200 in PBS) for 1 hour. They were washed 
with PBS/3% Triton-X 100 for 3 times (each time 5 minutes).Then the sections were 
incubated in mouse monoclonal anti CNPase (1:400 in PBS) in RT overnight. They were 
washed with PBS/3% Triton-X 100 for 3 times (each time 5 minutes). The sections were 
incubated in secondary antibody Cy3 (red) labelled rabbit anti mouse IgG (1:200 in PBS) 
for 1 hour. They were washed with PBS/3% Triton-X 100 for 3 times (each time 5 
minutes). Last, the sections were mounted with Fluorescence mounting medium with 
DAPI and covered with coverslips. 
 
2.2.2.5   Microscopic observation and statistical analysis 
The sections were visualized with a Leica DM RXA2 fluorescence microscope and 
measured by Leica QFluoro™ software. The number of the positive cells was counted in 
5 randomized fields in every section with gray matter and white matter counted evenly. 
Each group had 3 mice, except the  5 month old Plp-tg group which had 5 mice, and 5 
cervical spinal cord cross sections where randomly selected for each mouse. Single 
positive cells should be stained thoroughly by two dyes (red, blue/green, blue). Those 
dyed triply (red, green and blue) are considered to be double positive cells. Raw data 
were analyzed by One-way ANOVA with p <0.05 being considered as a significant. 
Since the cells are counted randomly, the comparison of ratio (positive cell number to 
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total cell number which is stained blue by DAPI) may represent the difference among 
groups better. And the rest of experiments, I all focus on the ratio and attached counting 
number for reference. 
 
2.2.3   OPC culture 
OPCs were isolated from the cortex of P0-P3 (0-3 days after birth) WT and Plp-tg mice 
pups based on previously described methods (Besnard et al., 1989; Laeng et al., 1994) 
with modifications. The modified culture procedures consist of two steps. The first one is 
the preparation of a primary culture, from brain of new born mice (until P3), which 
contain, after 10 days in vitro approximately 95% of OPCs. These cells are lying above 
astrocyte. In a second step, OPCs from the highly enriched culture are detached 
mechanically by syringing, taken advantage of the weak adhesion of these cells to the 
under layer of astrocytes. This allows further enrichment of OPCs in culture. 
 
2.2.3.1 Primary culture of OPCs 
Ten cm diameter petri dishes (Falcon) were coated with 0.01% poly-l-lysine overnight at 
37oC and washed 3 times with PBS before using. Instruments, including scissors and fine 
forceps were sterilized. One ml L-15 medium (Gibco) was placed in each of 15 ml tubes 
(Falcon) and the tubes were put on ice. Five ml sterile PBS was put in a 65 mm petri dish 
(Iwaki) and the dish was put on ice. The dissection microscope was set up. 
 
Mouse pups were sacrificed by decapitation. A scalpel was used to remove the skin from 
the skull. A scissor was used to open the skull and the whole brain was carefully removed 
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into the petri dish containing icy PBS. The cerebral hemispheres were carefully removed 
and the meninges were detached from the hemispheres by two fine forceps under the 
dissection microscope. The tissue was put into a tube containing L-15 medium. The pups’ 
tails were cut at the same time for later genotyping. Until all the pups were sacrificed, L-
15 medium was discarded and 1 ml 0.25%Trypsin/0.5mM EDTA was added to each of 
the tube containing the tissue. These tubes were incubated at 37°C for 20 minutes, during 
which the 15 ml tubes were shook vigorously every 5 minutes. 
After 20 minutes, the tissues were pipetted until no visible tissue block and they were 
dispersed thoroughly. Four ml OPC1 medium were added to stop trypsinization. Five ml 
or 10ml Pasteur pipettes were used to homogenize the digested tissue (cell clump mixture) 
for ten times. The mixtures were centrifuged at 100g for 10 minutes and the supernatant 
was discarded. The cells were resuspended in OPC1 medium. The cells in each 15ml tube 
(Falcon) were filtered through cell strainers (40 or 70μm pore size) and plated into one 
separate 110cm diameter petri dish (Falcon) coated with poly-l-lysine. After 3 days, the 
medium was changed with fresh and was changed twice per week afterwards. 
 
2.2.3.2 Secondary culture of OPCs 
Coverslips were coated in 4-well flask (Falcon) with 0.01% poly-l-lysine overnight at 
37oC and washed 3 times with PBS before using. After 10-14 days in vitro culture, OPCs 
were detached from a confluent cell layer by gentle syringing culture medium (OPC1 
medium), with a 20ml syringe (with a 2mm needle). About 2/3 of the OPCs can be easily 
removed.  
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From the genotyping results, the same gene background cells suspension (wt or Plp-tg) 
were put into same 50ml Falcon tubes. The resulting cells were plated onto bacterial Petri 
dishes for about 30 minutes to allow adhesion of contaminating astrocytes and microglia. 
The non-adherent cells were then collected and centrifuged at 100g for 10 minutes. The 
pellets were resuspended in OPC2 medium and homogenized with a Pasteur pipette.The 
cells were counted and seeded on coverslips in 4-well flask (Falcon) coated with 0.01% 
poly-l-lysine at the density of 4×104 cells/cm2. 
The medium was changed 1 day after seeding. Every day PDGF and bFGF were 
replenished to the cells and every other day the medium was changed completely. After 
an additional 3 days, the cells were ready to be used testing the proliferation rate by 
BrdU-incorporation test. 
 
Table 3.  500 ml OPC1 medium composition 
445 ml DMEM/F12 (1:1) with L-glutamine Gibco 
5ml 100× penicillin/streptomycin Sigma 
50ml FBS Sigma 
3g Glucose Sigma 
 
Table 4.  50 ml OPC2 medium composition 
46ml DMEM/F12 (1:1) with L-glutamine Gibco 
0.225g glucose Sigma 
3.3ml 1% bovine serum albumin (BSA) Sigma 
3.5μl D-biotin (0.2mg/ml) Sigma 
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0.18g NaHCO3 Sigma 
1μl triiodothyronine (T3) (30nmol/l) Sigma 
0.25ml FBS Sigma 
0.5ml 100× penicillin/streptomycin Sigma 
5μl  basic fibroblast growth factor (bFGF) 
(10ng/ml) 
Sigma 




2.2.4 In vitro OPC proliferation assay 
2.2.4.1   BrdU treatment, fixation and blocking 
Cells were cultured on 13 mm coverslips. BrdU were added in opc2 medium to make the 
final concentration of BrdU to 10μM. Cell culture medium was changed to 10μM BrdU 
OPC2 medium and cells were let to grow in this medium for 24 hours. After washing 
twice with PBS, cells were fixed with 4% paraformaldehyde at RT for 20 minutes and 
washed once with PBS and once with PBS/Triton-X 100 to increase the permeability of 
the cell membrane. Cells were then blocked with 1% BSA at RT for 20 minutes to 
decrease non-specific binding of antibodies. 
4% paraformaldehyde was made as follows: 
          4 g paraformaldehyde powder (Sigma) 
          100 ml PB buffer (pH 7.4) 
100 ml PB buffer (pH 7.4): 
          1.0488 g NaH2PO4•H2O (Merck) 
          4.6008 g Na2HPO4•7H2O (Merck) 
PBS/Triton-X 100: 
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          10 ml PBS 
          20 μl Triton-X 100 (Sigma) 
 
2.2.4.2   Antibody incubation 
The cells were first immunostained for NG-2. The cells were incubated on the coverslips 
with primary antibody (rabbit anti-mouse NG2 polyclonal 1:200) at RT overnight, after 
which they were washed three times with PBS and incubated with 488-labelled goat anti-
rabbit secondary antibody (1:200) at RT for 1 hour. The sections were subsequently 
washed three times with PBS. 
 
The cells were next immunostained for BrdU. The cells on the coverslip were incubated 
with trypsin in PBS for 10 minutes and rinsed 5 minutes for 3 times in PBS. The cells 
were next incubated in 2N HCl in PBS for 30 minutes.  They were then rinsed in PBS 5 
minutes for 3 times. After this, the cells were incubated with mouse monoclonal anti 
BrdU antibody (1:100 in PBS) overnight at RT and then rinsed 5 minutes for 3 times in 
PBS. Next the cells were incubated with Cy3-labelled rabbit anti-mouse IgG secondary 
antibody (1:200) at RT for 1 hour. After all these procedures, the cells were thoroughly 
rinsed with PBS and were allowed to dry in the dark. Finally, the cells were mounted 
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2.2.4.3   Microscopic observation and statistical analysis 
Cells were visualized with a Leica DM RXA2 fluorescence microscope and measured by 
Leica QFluoro™ software. The number of positive cells was counted in 15 randomized 
fields in 3 independent experiments in each group. Photos were taken using the same 
optical parameters to ensure comparable luminosity. Nine hundred cells from three 
independent experiments were counted. Raw data were analyzed by Student’s t test with 
p < 0.05 being considered as a significant. 
 
2.2.5 Assessment of in vivo OPCs proliferation  
The protocol adapted from Cai et al (1997), used the thymidine analog 5-bromo-2’-
deoxyuridine (BrdU), which can incorporate into DNA during cell division and can be 
recognized by a specific antibody.  
 
2.2.5.1 BrdU injection  
The BrdU (6 mg/ml) was intraperitoneally injected to WT mice and Plp-tg mice (0.1 ml / 
20 g weight) 6 times per day at intervals of 2 hours. Groups of mice injected are at the 
age of 1 month-, 2 months- and 7 months-old and each time point there were 3 mice 
/group. Twenty-four hours after injection, these mice are sacrificed and perfused. 
 
2.2.5.2   Perfusion and dehydration 
Plp-tg mice of 1 month-, 2months-, 7months- old and WT mice of 1 month-, 2months-, 
7months- old that were intraperitoneally injected BrdU 24 hours ago were deeply 
anesthetized with 7% chloride hydrate and transcardially perfused with Ringer’s solution, 
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followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB) (pH 7.4). The 
cervical spinal cord was removed and post-fixed in the same fixative for another 2 days. 
Then the tissue was transferred to 15% sucrose solution at 4°C overnight and then to 30% 
sucrose solution overnight to dehydrate. 
 
2.2.5.3   Cryosectioning 
See 2.2.2.2 
 
2.2.5.4 Permeabilization and blocking 
See 2.2.2.3 
 
2.2.5.5 Antibody incubation 
The sections were incubated with primary antibody (rabbit anti-mouse NG2 polyclonal 
1:200) at RT overnight, after which they were washed three times with PBS and 
incubated with 488-labelled goat anti-rabbit secondary antibody(1:200) at RT for 1 hour. 
The sections were subsequently washed three times with PBS. The sections were 
incubated with trypsin in PBS for 10 minutes then rinsed in PBS 5 minutes for 3 times. 
The sections were then incubated in 2N HCl in PBS for 30 minutes and then rinsed 5 
minutes for 3 times. The sections were then incubated with mouse monoclonal anti-BrdU 
antibody (1:100 in PBS) overnight at RT. The sections were rinsed in PBS 5 minutes for 
3 times. Next the sections were incubated with Cy3-labelled rabbit anti-mouse IgG 
secondary antibody (1:200) at RT for 1 hour. After all these procedures, the sections were 
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thoroughly rinsed with PBS and were allowed to dry in the dark and mounted with 
fluorescent mounting medium with DAPI. 
 
2.2.5.6 Microscopic observation and statistical analysis 
The sections were visualized with a Leica DM RXA2 fluorescence microscope and 
measured by Leica QFluoro™ software. The number of the positive cells was counted in 
5 randomized fields in every section. Each group had 3 mice and each mouse is randomly 
chosen 5 cervical spinal cord cross sections. Raw data were analyzed by One-way 
ANOVA with p <0.05 being considered as a significant. 
 
2.2.6 Double immunostaining for CNPase and activated caspase-3 in spinal cord 
2.2.6.1   Perfusion and dehydration 
Five months old Plp-tg mice and  5months- old WT mice were deeply anesthetized with 
7% chloride hydrate and transcardially perfused with Ringer’s solution, followed by 4% 
paraformaldehyde in 0.1 M sodium phosphate buffer (PB) (pH 7.4). The cervical spinal 
cord was removed and post-fixed in the same fixative for another 2 days. Then the tissue 
was transferred to 15% sucrose solution at 4°C overnight and then to 30% sucrose 
solution overnight to dehydrate. 
 
2.2.6.2   Cryosectioning 
See 2.2.2.2 
 
2.2.6.3   Permeabilization and blocking 
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See 2.2.2.3 
 
2.2.6.4   Antibody incubation 
1. The sections were incubated in Rabbit anti mouse active Caspase-3 (1:100 in PBS) 
polyclonal antibody in RT overnight. They were washed with PBS/3% Triton-X 100 for 3 
times (each time 5 minutes).Next, the sections were incubated in secondary antibody 
Alexa Fluor® 488(green) labelled goat anti rabbit IgG (1:200 in PBS) for 1 hour. Then 
they were washed with PBS/3% Triton-X 100 for 3 times (each time 5 minutes). After 
that, the sections were incubated in mouse monoclonal anti CNPase (1:400 in PBS) in RT 
overnight. They were washed with PBS/3% Triton-X 100 for 3 times (each time 5 
minutes). Next the sections were incubated in secondary antibody Cy3 (red) labelled 
rabbit anti mouse IgG (1:200 in PBS) for 1 hour. They were then washed with PBS/3% 
Triton-X 100 for 3 times (each time 5 minutes). Last, the sections were mounted with 
Fluorescence mounting medium with DAPI and cover with coverslip. 
 
2.2.6.5   Microscopic observation and statistical analysis 
The sections were visualized with a Leica DM RXA2 fluorescence microscope and 
measured by Leica QFluoro™ software. The number of the positive cells was counted in 
5 randomized fields in every section with gray matter and white matter counted evenly. 
Each group had 3 mice, except the  5 month old Plp-tg group which had 5 mice, and 5 
cervical spinal cord cross sections where randomly selected for each mouse. Single 
positive cells should be stained thoroughly by two dyes (red, blue/green, blue). Those 
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dyed triply (red, green and blue) are considered to be double positive cells. Raw data 
were analyzed by One-way ANOVA with p <0.05 being considered as a significant. 
 
2.2.7 CD11b immunostaining in spinal cord 
2.2.7.1   Perfusion and dehydration 
Plp-tg mice of 3 months-, 5months-, 7months- old and WT mice of 5months- old were 
deeply anesthetized with 7% chloride hydrate and transcardially perfused with Ringer’s 
solution, followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB) (pH 
7.4). The cervical spinal cord was removed and post-fixed in the same fixative for 
another 2 days. Then the tissue was transferred to 15% sucrose solution at 4°C overnight 
and then to 30% sucrose solution overnight to dehydrate. 
 
2.2.7.2   Cryosectioning 
Please see 2.2.2.2 
 
2.2.7.3   Permeabilization and blocking 
The sections were permeabilized by washing with PBS/3% Triton-X 100 for 3 times 
(each time 10 minutes) and with 4°C  acetone for 15 minutes. Then the sections were 
washed with PBS/3% Triton-X 100 3 times (each time for 5 minutes). The tissue sections 
were incubated in 0.3% hydrogen peroxide in PBS for 30 minutes to block endogenous 
peroxidase activity and then again washed with PBS/3% Triton-X 100 3 times (each time 
for 5 minutes). The sections were then blocked with 10% goat serum in PBS/3% Triton-
X 100 at RT for 1 hour. 
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2.2.7.4   Antibody incubation 
The sections were incubated with the primary antibody, mouse monoclonal anti CD11b 
(1:100 in PBS), at room temperature overnight. They were then washed with PBS/3% 
Triton-X 100 3 times (each time for 5 minutes). Next the sections were incubated with 
the secondary antibody, biotinylated rabbit anti-mouse IgG (1:200 in PBS) for 1 hour. 
The sections were washed with PBS/3% Triton-X 100 for 3 times (each time 5 
minutes).The Sections were incubated for 5-10 minutes with ABC Reagent. They were 
then washed with PBS/3% Triton-X 100 for 3 times (each time 5 minutes). The sections 
were incubated in peroxidase substrate (DAB) solution until desired stain intensity 
develops. They were washed with PBS/3% Triton-X 100 for 3 times (each time 5 
minutes). The sections were dipped in sequence in 50% alcohol, 70% alcohol, 80% 
alcohol, 90% alcohol, 100% alcohol (twice), xylene (twice), each time 5 minutes to 
dehydrorate and clear sections.The sections were mounted with mounting medium and 
cover with coverslip.  
 
2.2.7.5   Microscopic observation and statistical analysis 
The sections were visualized with a Leica DM RXA2 fluorescence microscope and 
measured by Leica QFluoro™ software. The number of the positive cells was counted in 
5 randomized fields every section with gray matter and white matter counted evenly. 
There were 3 mice in each group and 5 cervical spinal cord cross sections were randomly 
selected from each mouse. The data were analyzed by One- way ANOVA, with p < 0.05 
being considered as a significant. 
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2.2.8 Spinal cord cross section CD4 and CD8 immunostaining. 
2.2.8.1   Perfusion and dehydration 
Plp-tg mice of 3 months-, 5months-, 7months- old and WT mice of 5months- old were 
deeply anesthetized with 7% chloride hydrate and transcardially perfused with Ringer’s 
solution, followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB) (pH 
7.4). The cervical spinal cord was removed and post-fixed in the same fixative for 
another 2 days. Then the tissue was transferred to 15% sucrose solution at 4°C overnight 
and then to 30% sucrose solution overnight to dehydrate. 
 
2.2.8.2   Cryosectioning 
See 2.2.2.2 
 
2.2.8.3   Permeabilization and blocking 
See 2.2.2.3 
 
2.2.8.4   Antibody incubation 
The sections were incubated in FITC-labelled anti-CD4 (L3T4) mouse monoclonal 
(1:100 in PBS) or FITC-labelled anti-CD8 (L3T4) mouse monoclonal antibody in RT 
overnight. They were washed with PBS/3% Triton-X 100 for 3 times (each time 5 
minutes).Then the sections were mounted with Fluorescence mounting medium with 
DAPI and cover with coverslip. 
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2.2.8.5   Microscopic observation and statistical analysis 
The sections were visualized with a Leica DM RXA2 fluorescence microscope and 
measured by Leica QFluoro™ software. The number of the positive cells was counted in 
5 randomized fields in every section with gray matter and white matter counted evenly. 
Each group had 3 mice, except the  5 month old Plp-tg group which had 5 mice, and 5 
cervical spinal cord cross sections where randomly selected for each mouse. Positive 
cells should be stained thoroughly by two dyes (green, blue). Raw data were analyzed by 
One-way ANOVA with p <0.05 being considered as a significant. 
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3.1 Immature to mature oligodendrocyte ratio in Plp-tg mouse spinal cord  
A number of markers have been used to define the stages of OLs development (see 
Figure 1 of Chapter 1 INTRODUCTION). We investigated whether demyelination in 
CNS, and especially in spinal cord, of Plp-tg mice arises from a decrease in the number 
of mature oligodendrocytes. We used NG2 as the marker of OPCs or immature 
oligodendrocytes and CNPase as a marker of mature oligodendrocytes. We 
immunostained the spinal cord sections from Plp-tg mice and WT mice with anti-NG2 
and anti-CNPase antibodies to study the mature OLs number (CNPase+ve cells) and 
immature OLs (NG2+ve cells) number in two groups, and the ratio of NG2+ve cells to 
CNPase+ve cells as measure of the ratio of immature to mature OLs.  
 
3.1.1 Two months after birth, Plp-tg mice spinal cords have an elevated NG2 to 
CNPase-positive oligodendrocytic cell ratio. 
When they were two months-old, the Plp-tg mice had more NG2+ ve cells, less 
CNPase+ve cells and a greater NG2 +ve to CNPase +ve cell ratio than their WT 
littermates. (p < 0.05; Figure. 3). Hence, the Plp-tg mice have much higher immature to 
mature OLs ratio than WT mice. The relative lack of mature oligodendrocytes resulting 
in a failure to maintain myelination may explain why the Plp-tg mice begin to show 
demyelination at this time. We next investigated the change in the immature to mature 
oligodendrocyte ratio at different time points to determine whether the change in the ratio 
was maintained throughout the development of the pathology.  
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Figure 3 Two month Plp-tg mice and WT mice immature/mature oligodendrocyte 
























CNPase+ mature oligodendrocytes and Ng2+ immature oligodendrocytes in spinal cord 
of 2- months Plp-tg mice (A) and WT mice (B). Figure C shows the comparison of 
NG2R (Ng2+ cell number/total cell number), CNPaseR (CNPase+ cell number/total cell 
number) and NG2/CNP (Ng2+ cell number/ CNPase+ cell number) in spinal cord 
between WT and Plp-tg mice. The WT littermates have lower NG2R (P<0.05), higher 
CNPaseR (P<0.01) and lower NG2/CNP (P<0.01) than Plp-tg mice. Scale bar in (A): 25 
μm. 
                   
Table 5. Two month Plp-tg mice and WT mice immature/mature oligodendrocyte 
 
 
 Total number CNPase+ Ng2+ Ng2+ ratio CNPase+ ratio Ng2+/CNPase+ ratio
       
WT 44.15±14.91 21.85±10.91 8.46±7.49 0.19±0.13 0.51±0.19 0.43±0.27 
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3.1.2 The highest immature to mature OLs ratio occurs in 5 months-old Plp-tg mice 
We use 5-month-old WT littermates as a control, and looked at the NG2 +ve to CNPase 
+ve ratio in 3-, 5- and 7-month-old Plp-tg mice. The 5-month-old Plp-tg mice had less 
CNPase +ve cells and more NG2 +ve cells than WT mice at the same age. Three- , 5- and 
7-month-old Plp-tg mice all had higher NG2 +ve to CNPase +ve ratios than 5-month WT 
mice. Taken together with the previous experiment, these data show that in the Plp-tg 
group, the mice begin to show a reversed immature to mature oligodendrocyte (NG2 +ve  
to CNPase +ve) ratio (p < 0.05) from at least 2 months old. The ratio continues to 
increase up to 5 months old, when it peaks and subsequently drops by 7 months of age 
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CNPase+ mature oligodendrocytes and Ng2+ immature oligodendrocytes (opcs) in spinal 
cord of 5- month WT mice(a), 3-months old Plp-tg mice(b), 5-months old Plp-tg mice(c) 
and 7-months old Plp-tg mice(d). Figure e shows the CNPase+ cell number and NG2+ 
cell number comparison in spinal cord of 4 groups. If let the NG2+ cell number/CNPase+ 
cell number ratio of WT mice=1, we can see the other three groups NG2+ cell 
number/CNPase+ cell number ratio comparing with WT mice (f). Scale bar in (a): 25 μm. 
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Table 6          Plp-tg mice and WT mice immature/mature oligodendrocyte 
 
 Ng2+ CNPase+ Ng2+/CNPase+ ratio 
WT 16.52±6.28 14.99±4.57 1.13±0.39 
PLP3m 9.67±4.69 10.48±3.92 1.00±0.52 
PLP5m 20.92±6.30 18.64±4.70 1.14±0.32 
PLP7m 11.56±7.88 14.00±7.54 0.93±0.54 
 
3.2 In vitro OPC proliferation  
We next proceed to investigate the mechanisms underlying the change in the ratio of 
immature to mature oligodendrocytes. To investigate whether the difference might arise 
from a change in the rate of proliferation of OPCs, we carried out in vitro OPC 
proliferation assay. After two culture steps, primary OPCs from the cortex of P3 (3 days 
after birth) Plp-tg pups and WT pups were cultured in coverslips. After cells 
incorporating of BrdU for 24 hours, NG2 and BrdU double immunostaining was carried 
out to test whether the proliferation rate of OPCs was different between the two groups. 
From Figure 5, we can see that the Plp-tg mice and wild type mice have the similar OPC 
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Ng2+ ve oligodendrocyte precursor cells (a) and BrdU+ve proliferating cells (b) in Plp-tg 
mice cells. Ng2+ oligodendrocyte precursor cells (c) and BrdU+ proliferating cells (d) in 
WT mice cells. Figure e shows there’s no difference in NG2 difratio (NG2+ and BrdU+ 
cells/ NG2+ cells) and NG2ratio (NG2+cell/total cell number) between WT and Plp-tg 
mice(P>0.05). Scale bar in (A): 25 μm. 
 
 
Chapter 3: Results                                                                                                              40 
Table 7 In vitro Opc proliferation comparison 
 
 Total  Ng2+ Ng2+ and Brdu+ Ng2+ difratio Ng2+ratio 
WT 38.00±11.43 29.00±9.27 28.00±9.58 0.96±0.06 0.77±0.11 
PLP 41.91±13.24 32.08±11.74 31.50±12.12 0.97±0.05 0.76±0.10 
 
3.3 In vivo OPC proliferation 
To confirm the absence of any difference in proliferation rate of OPCs, we carried out in 
vivo OPC proliferation assay. After 24 hours of injection of BrdU, double 
immunostaining of NG-2 and BrdU was performed in 1 month, 2 months and 7 months 
old groups. In each time point, Plp-tg and WT mice were compared. From Figure6, we 
can see that, regardless of whether the mice were 1 month, 2 months or 7 months old, 
proliferation rate of OPCs in the Plp-tg and WT mice remained similar (no significance, 
P > 0.05). These results confirm that there is no difference in the proliferation rate of 
OPCs in Plp-tg mice compared to WT mice. This implies that the increase in the number 
of immature relative to mature oligodendrocytes is not due to an increase in the rate of 
proliferation of immature oligodendrocytes.  
 
Consistent with the previous findings on the NG2 +ve to CNPase +ve cell ratio, the 
number of NG2 +ve cells was increased relative to the WT controls at 2 months old. 
However, at 1 month old, the number of NG2+ ve cells remained similar in Plp-tg and 
WT mice (p > 0.05). This suggests that the increase in the number of immature OLs first 
appears between 1 month and 2 months of age and that the Plp-tg mice probably begin to 
show the change in the ratio of immature to mature oligodendrocytes at this time.   
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Figure 6 oligodendrocyte precursor cells (OPCs) proliferation comparision 
























































BrdU+ proliferating cells and Ng2+ oligodendrocyte precursor cells (OPCs) in spinal 
cord of 1- month old WT mice(a), 1-month old Plp-tg mice(b), 2-months old WT mice(c), 
2-months old Plp-tg mice(d), 7-months old WT mice(e) and 7-months old Plp-tg mice(f). 
In one month group (g), there is no difference in BrdUR (total proliferating cells: 
BrdU+/total cell number), Ng2R (total OPCs: NG2+/total cell number) and Ng2DiffR 
(proliferating opcs: NG2+ and BrdU+/NG2+) between WT and Plp-tg mice (P>0.05). In 
two month group (h), WT mice have lower NG2R than Plp-tg group (P<0.05), the other 
ratio is similar (P>0.05). In 7-months old group (i), except WT mice have lower NG2R 
than Plp-tg group, the other ratio is similar(P>0.05). Scale bar in (A): 25 μm. 
 
Table 8 oligodendrocyte precursor cells (OPCs) proliferation comparision 
 Total Brdu+ Ng2+ Brdu+ and Ng2+ Brdu+R Ng2+R Ng2+DiffR
WT1m 56.00±26.79 22.50±12.13 17.20±5.16 10.70±4.62 0.41±0.12 0.34±0.11 0.23±0.13 
PLP1m 89.00±8.11 40.40±12.77 33.60±9.42 23.70±6.75 0.46±0.15 0.38±0.10 0.26±0.08 
WT2m 80.38±35.69 38.25±19.64 21.50±6.12 13.88±4.94 0.48±0.11 0.30±0.12 0.20±0.09 
PLP2m 102.58±28.72 42.00±9.73 50.43±10.72 28.29±5.41 0.42±0.09 0.51±0.11 0.29±0.07 
WT7m 98.00±72.12 54.50±37.48 33.00±12.02 23.50±7.07 0.56±0.07 0.40±0.16 0.28±0.17 
PLP7m 58.80±36.11 29.60±19.35 30.60±22.61 19.60±15.95 0.54±0.23 0.50±0.07 0.33±0.10 
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3.4 Rate of apoptosis of OLs  
Mature OLs derive from their precursor cells-- the OPCs. Since Plp-tg mice have more 
OPCs and less mature OLs than WT mice, while the two groups have similar rates of 
OPCs proliferation, we hypothesised that an increase in the rate of mature 
oligodendrocyte apoptosis might explain the difference in the ratio of immature to mature 
oligodendrocytes. Caspase-3 is a key factor in both of the two classic apoptosis pathways: 
the microcondria-dependent and -independent pathways. We used double 
immunostaining for active caspase-3 and CNPase to assess the apoptosis of mature OLs 
of 5 months-old Plp-tg and WT mice. From Figure 7, we can see that Plp-tg mice had 
greater rates of mature OLS apoptosis than WT mice (p < 0.05). The above results show 
that Plp-tg mice have more immature OLs and less mature OLs than WT mice from the 
age of 2 months. The difference is not caused by a change in the rate of OPC proliferation. 
The decreased mature OLs number in Plp-tg mice appears to be explained by the higher 
incidence of mature OLs apoptosis. Though Plp-tg mice have more OPCs/immature OLs, 
this is not caused by a higher rate of proliferation (no significant difference). So with the 
similar OPC proliferation rate, there are more OPCs in Plp-tg mice. The impairment of 
differentiation and the higher rate of apoptosis together cause a reduction in mature OLs 
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Active caspase-3+ apopotosis cells (a), CNPase+ mature oligodendrocytes (b) and merge 
graph (C) in spinal cord of 5-months old WT mice. Active caspase-3+ apopotosis cells 
(d), CNPase+ mature oligodendrocytes(e) and merge graph (f) in 5-months old Plp-tg 
mice. (g)In the apopotosis mature oligodendrocyte (caspase-3+ and CNPase+) 
comparison, Plp-tg mice have more apoptosis mature oligodendrocytes (P<0.05). Scale 
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3.5 Microglia phagocytosis  
Inoue et al. (Inoue et al., 1996) found activated microglia-like cells in the optic nerves of 
2-month-old Plp-tg mice. We studied the change in the number of microglia in spinal 
cord during the course of demyelination using CD11b as a marker and 5 month old WT 
mice as controls. From Figure 9, we can see that 5-month-old Plp-tg mice have more 
CD11b+ve microglia in spinal cord than WT mice (p < 0.05). But within the Plp-tg mice 
group, the number of CD11b+ve microglia in spinal cord is not significant different at 
ages of  3 months, 5 months and 7 months  (p > 0.05). This suggests that microglia may 
be involved in the demyelination process, perhaps by inducing apoptosis of mature OL or 
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WT Plp3m Plp5m Plp7m










CD11b+ microglia cells in spinal cord of 5-months old WT mice (a), 3-months old Plp-tg 
mice (b), 5-months old Plp-tg mice(c) and 7-months old Plp-tg mice. The 3-months old 
Plp-tg mice, 5-months old Plp-tg mice and 7-months old Plp-tg mice all have more 
microglia cells than 5-months old WT mice (p<0.05). Scale bar in (a): 25 μm. 
 
Table 9. microglial cell in spinal cord comparision 
Group WT PLP3m PLP5m PLP7m 
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3.6 T cell infiltration  
Since microglia cells in MS are induced by CD4+ ve T cells, we next investigated the 
number of CD4+ve T cells and CD8+ve T cells. These cell types represent the major part 
of the T cell population and play a vital role in the immune response. We studied 
3months-, 5months-, and 7moths old Plp-tg mice and 5 months old WT mice as controls. 
Figure 9 shows that compared with the WT group, the Plp-tg mice have more CD4+ve T 
cells and CD8+ve T cells in their spinal cords. The CD4+ve T cell number increases 
gradually as the mice get older and demyelination proceeds (p < 0.05), while the CD8+ve 
T cell number remains similar (p > 0.05) as the mice getting older. CD4+ve T cell can 
induce microglia activation via cytokines and induce B cell immune response. Thus, 
consistent with what is known of the MS and the EAE model, the CD4+ve T cell and 
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CD4+ T cells infiltration in spinal cord of 5-months old WT mice (a), 3-month Plp-tg 
mice (b), 5-months old Plp-tg mice(c) and 7-months old Plp-tg mice (d). CD8+ T cells 
infiltration in spinal cord of 5-months old WT mice (e), 3-months old Plp-tg mice (f), 5-
months old Plp-tg mice (g) and 7-months old Plp-tg mice (h). Figure (i) shows 3-months 
old Plp-tg mice, 5-months old Plp-tg mice and 7-months old Plp-tg mice have more 








Discussion  and 
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4.1                                                  Discussion                                             
4.1.1 Primary cause of chronic demyelination and impairment of remyelination  
Compared to WT mice, the number of mature OLs (CNPase +ve) in spinal cord of Plp-tg 
mice (Plp tg/-) was decreased, while the number of OPCs (NG2 +ve) was increased from 2 
months of age. In Plp-tg mice, the ratio of NG2 +ve to CNPase +ve cells increased from 
2 months of age, reached a peak at 5 months old, and then decreased. The demyelination 
of the Plp-tg mice coincided with the deficit in mature oligodendrocytes, but the decrease 
in mature oligodendrocytes does not arise from a decrease in OPCs, on the contrary their 
population is increased. We found greater apoptosis of mature OLs in Plp-tg mice than 
WT mice. This may be one reason for the decrease in mature OLs. But both in vitro and 
in vivo experiments showed that the OPCs in Plp-tg mice and WT mice have similar rates 
of proliferation. Thus, the increased population of OPCs in Plp-tg mice is not explained 
by increased OPC proliferation. Together these data suggest that the reduction of mature 
OLs in Plp-tg mice cannot be the result only of greater apoptosis rate of mature OLs but 
most likely also reflects a deficit in OPC differentiation into mature OLs. Both the deficit 
in maturation and the increased apoptosis of mature OLs probably contribute to chronic 
demyelination and impairment of remyelination in Plp-tg mice. 
 
4.1.2 Other models of MS with similar pathology  
In the Theiler's murine encephalomyelitis virus (TMEV) induced MS model, TMEV 
significantly upregulates the expression of cytokines involved in innate immunity, MHC 
class II, IL-12, and various costimulatory molecules. TMEV-infected microglia were able 
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to present antigen to CD4+ Th1 cells and lead to the activation of naive and memory 
adaptive immune responses which caused CNS demyelination (Olson et al., 2001). 
 
To clarify the involvement of OLs death in EAE, Hisahara et al. (2000) generated 
transgenic mice that express the baculovirus anti-apoptotic protein p35 in OLs. OLs from 
the transgenic mice were resistant to TNF–α, anti-Fas antibody- and IFN–γ-induced cell 
death. The transgenic mice were resistant to EAE induction. They found that not only the 
apoptotic OLs expressing the activated form of caspase–3 but infiltrating T cells and 
macrophages/microglia in the EAE lesions were significantly reduced (Hisahara et al., 
2000). This finding proves apopotosis in OLs plays an important role in the EAE model. 
 
Some indirect evidence also suggests that the pro-inflammatory cytokines such as TNF–
α , IFN–γ, and Fas are important in mediating OLs death in MS and EAE (D'Souza et al., 
1996; Ledeen, Chakraborty, 1998). 
 
OPCs increase in the EAE model and our Plp-tg model. Inflammatory cells (lymphocytes 
and microglia) have been proved to enhance the migration of OPCs and secrete different 
growth factors to stimulate proliferation of OPCs in the EAE model (Tourbah et al., 
1997; Kerschensteiner et al., 1999). But little is known about the arrest of terminal 
differentiation in OPCs. Besides the intrinsic mechanisms, CD4+ve T cells and microglia 
are supposed to have some relation with the failure of maturation in OLs. Stephen A 
Back et al. (2005) found that hyaluronan accumulates in demyelinated lesions in MS 
patients and in EAE mice, which could inhibit maturation of OPCs in vitro and in vivo. 
Chapter 4: Discussion & Conclusions                                                                         51                               
CD4+ve T cells, microglia and astrocytes are the main source of glycosaminoglycan 
hyaluronan, and they are believed to be connection with the arrest of OPC maturation 
(Back et al., 2005). Mummert et al. (2002) also found that hyaluronan is expressed on 
dendritic cells and has the function of antigen presenting (Mummert et al., 2002). 
Hyaluronan and CD44, which is mainly expressed by CD4+ve T cells and microglia, 
were found to interact in the inflammatory response (Wang et al., 2001). It is likely that 
CD4+ T cells and microglia together with intrinsic cellular factors cause the failure of 
remyelination (Figure 10).  
 
4.1.3 Cascade immune respond in Plp-tg mice 
Previously researchers have reported extensive microglia in the CNS of Plp-tg mice 
(Kagawa et al., 1994; Inoue et al., 1996). Consistent with these previous findings, we 
found a steady increase in CD11b +ve microglia in the spinal cord of Plp-tg mice from 3 
month to 7 month compared to WT mice. Moreover, we found that the increased 
microglial presence was accompanied by an increase in CD4+ve T cells and CD8+ve T 
cells in the spinal cord of Plp-tg mice. These findings may suggest that the demyelination 
is caused by autoimmunity. CD4+ve T cells, mostly TH1 cells, were activated by 
microglia or other APCs presenting antigens and produce many cytokines. These 
cytokines in turn activiate microglia further. It is possible that the cascade reaction caused 
by cytokines of CD4+ve T cell, CD8+ve T cell and microglia, phagocytosis of microglia 
and cytotoxic function of infiltrated activated CD8+ve T cells could increase mature OLs 
apoptosis and inhibit OPCs differentiation and hence induce the chronic demyelination 
and failure of remyelination seen in these mice (Figure 10).  
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4.1.4 Further work required to clarify the mechanisms  
Since the cell number comparison was mainly done by immunostaining, which is a semi-
quantitive method, confirmation by flow-cytometer sorting with double staining should 
be performed. Further research is needed to investigate whether CD4+ve T cells could 
secrete pro-inflammatory cytokines in Plp-tg mouse CNS, and to characterize the 
different molecular functions of TH1 and TH2 cells in the immune response in Plp-tg 
mice. Cytokines secreted by CD8+ve T cells and microglia cells should also be examined 
in the CNS. The role of immune modulator cells in regulating immune responses in Plp-
tg mouse CNS should also be considered. It is important to explore whether the signalling 
pathways of activation of CD8+ve T cells, CD4+ve T cells and microglia in the immune 
response in Plp-tg mice cross-talk with each other and with the apoptosis cascades. Large 
scale protein and DNA microarrays may help to solve those problems and procure further 
insights into the pathology of MS and other demyelinating diseases. Application of DNA 
vaccine and other immune treatment can also be considered both as methods to examine 
the mechanisms and as a potential therapy. 
 
4.1.5 Cellular mechanisms of demyelination and the failure of remyelination  
The mechanism of demyelination and the arrest of remyelination in Plp-tg mice is 
complicated. It is likely to be caused by changes both in the environment (autoimmune 
problem) and intrinsic cellular mechanisms. Kagawa et al. and Inoue et al. found that the 
protein level of PLP/DM-20 was low despite the increase in the mRNA level Plp-tg 
(Plptg/-) mice (Kagawa et al., 1994; Inoue et al., 1996), suggesting that the transport of 
PLP/DM-20 is affected in the transgenic mice. Since oligodendrocytes must produce and 
Chapter 4: Discussion & Conclusions                                                                         53                               
transport nearly 105 myelin protein molecules per minute and PLP/DM-20 forms 50% of 
the protein mass of myelin, an abnormal structure of PLP/DM-20 or its increase may 
cause a “traffic jam” in the rough endoplasmic reticulum-Golgi apparatus system 
(Pfeiffer et al., 1993). This block in the protein transport system might cause the arrest in 
maturation of the oligodendrocytes in the the Plp-tg (Plptg/-) mice. There is also evidence 
showing that Plp gene expression is related to the secretion of humoral factors which 
regulate the maturation and survival of oligodendrocytes. Kitagawa et al. (1993) and Yan 
et al. (1993) show that the Plp/DM-20 gene forms a gene family and that ion channel 
formation is a common feature of the members of this family. These diverse effects of 
PLP/DM-20 on oligodendrocyte maturation and survival might be explained by the 
formation of calcium ions which are known to exert various biological activities 
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Figure 10. Diagram summarising the mechanisms of demyelination in Plp-tg mice 
Maturation inhibited 
by CD4+, microglia, 
cellular intrinsic 
factors etc.
Cytokines released by 
CD4+,CD8+,microglia. 
Cytoxic effect by CD8+ 
and phagocytosis by 
microglia
Demyelination
and arrest in 
remyelination
 
Mature OLs derived from bipolar OPCs wrap target axons and form myelin. Cytokines 
are secreted by CD4+ve T cells, CD8+ve T cells and microglia, the cytotoxic effect of 
CD8+ve T cells and phagocytosis effect of microglia will induce apoptosis of mature 
OLs. CD4+, microglia together with the cellular intrinsic factors could possibly inhibit 
the maturation of OLs. These mechanisms will result in demyelination and arrest of 
remyelination in Plp-tg mice. 
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4.2                    Conclusion 
Plp-tg mice (Plptg/-), a demyelinating model of late MS, begin to show signs of 
demyelination from 2-3 months-old. Our finding that NG2+ ve OPCs in spinal cord of 1 
month-old Plp-tg mice are similar with WT mice is consistent with the previous findings 
that before 2 months old, the ultrastructure of myelin in Plp-tg mouse is normal. From 2 
months old, Plp-tg mice have less CNPase+ve OLs in spinal cord than WT mice which in 
turn causes impairment of remyelination. Our findings demonstrate that the decrease in 
CNPase+ve OLs is not caused by a lower number of progenitors—NG2+ve OPCs. From 
2 months-old, the Plp-tg mice have more NG2+ve OPCs in spinal cord than WT mice 
and hence they have a higher immature to mature OLs ratio. 
 
We proposed and investigated three hypotheses to explain why Plp-tg mice have more 
OPCs and less mature OLs than WT: (1) that the proliferation rate of OPCs in Plp-tg 
mice is less (2) that the apoptosis rate of mature OLs in Plp-tg mice is greater and (3) that 
the rate of differentiation from OPCs to mature OLs in Plp-tg mice is reduced. From our 
results, both in vitro and in vivo, and over a range of ages (3 days after birth, 1 month old, 
2 months old and 7 months old), the proliferation of NG2+ve OPCs in Plp-tg and WT 
mice are very similar. So the first hypothesis cannot explain the difference. Comparing 
apoptosis of mature OLs, we found that in Plp-tg mice there are higher ratio of apoptosis 
of mature OLs than in WT. Everything else being equal, then Plp-tg mice should have a 
similar number of OPCs to WT and less mature OLs than WT. But Plp-tg mice have 
more OPCs than WT. This is probably caused by failure of terminal differentiation of 
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OLs. So it is probably the high rate of apoptosis in mature OLs and failure of terminal 
differentiation of mature OLs that cause Plp-tg mice chronic demyelination and 
impairment of remyelination. 
 
Meanwhile, we found Plp-tg mice have more CD11b+ve microglia and CD4+ve, 
CD8+ve T cells in spinal cord than WT mice. As was discussed in Chapter 1, 
Introduction, these cells all play important roles in MS. Microglia can also act as APCs in 
CNS, initiating and propagating immune responses, phagocytosing dying cells and 
debris, and producing toxic innate effectors (Williams et al., 1994; Minagar et al., 2002; 
Nelson et al., 2002). The cytokines produced by CD4+ve T cells, CD8+ve T cells and 
microglia may probably inhibit oligodendrocyte terminal differentiation. Apoptosis of the 
mature OLs in Plp-tg mice is probably enhanced by the cytokines together with the 
CD8+ve T cell cellular toxic effect. Future work needs to be carried out to verifying this 
hypothesis. 
 
To sum up, this study suggests that the problem that leads to chronic demyelination and 
impairment of remyelination in Plp-tg mice probably lies in more OPCs and less mature 
OLs in CNS caused by a high rate of apoptosis in mature OLs and failure of terminal 
differentiation of mature OLs. The cytokines secreted by actived CD4+ve T cell, 
microglia and CD8+ve T cells together with CD8+ve T cell cytotoxic effects are most 
probably the underlying reasons. Better understanding of the mechanisms of the 
demyelination and the failure of remyelination in Plp-tg mice will better inform 
investigators using this model to find good therapies for MS. 
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